
<html>

<head>
<meta name="GENERATOR" content="Microsoft FrontPage 3.0">
<title>Nicotinamide in Type 1 Diabetes</title>
</head>

<body bgcolor="#FFFFFF">
<div align="left">

<table border="1" cellpadding="5" cellspacing="3" width="25">
  <tr>
    <td><font size="5"><b>Diabetes</b></font></td>
    <td bgcolor="#FFFFFF"><font color="#800040" size="5"><b>Care </b></font></td>
  </tr>
</table>
</div>

<p><font size="3" color="#800040"><strong>Volume&nbsp;22 Supplement 2 <br>
Improving Prognosis in Type 1 Diabetes<br>
Proceedings from an Official Satellite Symposium<br>
of the 16th International Diabetes Federation Congress</strong></font></p>
<div align="left">

<table border="0" cellpadding="5" cellspacing="3" width="600">
  <tr>
    <td><hr>
    <h2><font size="3"><em>These pages are best viewed with Netscape version 3.0 or higher or
    Internet Explorer version 3.0 or higher. When viewed with other browsers, some characters
    or attributes may not be rendered correctly.</em></font></h2>
    <hr>
    <p><strong><font color="#000000" size="3">ORIGINAL ARTICLE</font></strong></p>
    <hr>
    <p><font size="6">Nicotinamide in Type 1 Diabetes</font></p>
    <hr>
    <p><font face="Times New Roman" size="5">Mechanism of action revisited</font></p>
    <hr>
    <p><font size="3">Hubert Kolb, PHD<br>
    Volker Burkart, PHD</font></p>
    <hr>
    <p><font size="3">Treatment with high doses of nicotinamide (niacinamide, vitamin B3)
    prevents or delays insulin-deficient diabetes in several animal models of type 1 diabetes
    and protects islet cells against cytotoxic actions in vitro. In recent-onset type 1
    diabetes, nicotinamide administration improves <img src="../supplement299/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cell function, without significantly decreased
    insulin requirements. This review discusses the possible mechanism of action of
    nicotinamide in vivo. It is proposed that the key target of nicotinamide is the
    poly(ADP-ribose)polymerase (PARP), and to a lesser extent (mono)ADP-ribosyl transferases
    (ADPRTs). Suppression of PARP activity by nicotinamide not only decreases consumption of
    NAD<sup>+</sup></font><big>, </big>the substrate of PARP, but also has major regulatory
    effects on gene expression, as shown for the major histocompatibility complex class II
    gene. In addition, PARP activity controls early steps of apoptosis. The possible
    suppression of ADPRTs by nicotinamide would also affect CD38, a membrane-bound external
    ADP-ribosyl transferase with potent immunoregulatory properties. Taken together, it is
    proposed that high doses of nicotinamide primarily affect ADP-ribosylation reactions in <img src="../supplement299/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cells as well as in
    immune cells and the endothelium. As a consequence, cell death pathways and gene
    expression patterns are modified, leading to improved <img src="../supplement299/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cell survival and an altered immunoregulatory
    balance.</p>
    <p ALIGN="RIGHT"><font size="3"><i>Diabetes Care</i> 22 (Suppl. 2):B16&#150;B20, 1999</font></p>
    <hr>
    <p><strong><big><big>T</big></big></strong><font size="3">he B vitamin nicotinamide is
    presently being tried in several large studies of preventing type 1 diabetes (<a href="../supplement299/B16.asp#1">1</a>&#150;<a href="../supplement299/B16.asp#3">3</a>). These trials and previous pilot
    studies (<a href="../supplement299/B16.asp#4">4</a>&#150;<a href="../supplement299/B16.asp#6">6</a>) are based on reports of
    an antidiabetic effect of high-dose nicotinamide in animals.</font></p>
    <p><font size="3">At first, nicotinamide was successfully used to inhibit or mitigate the
    diabetogenic action of the <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cell toxins alloxan and streptozotocin (<a href="../supplement299/B16.asp#7">7</a>,<a href="../supplement299/B16.asp#8">8</a>). This prompted Yamada et al. (<a href="../supplement299/B16.asp#9">9</a>) to try high-dose nicotinamide for the prevention of autoimmune
    diabetes in NOD mice. As they reported in 1982 (<a href="../supplement299/B16.asp#9">9</a>), prophylactic
    treatment with nicotinamide suppressed the development of diabetes and reduced the
    insulitis grade. These findings were confirmed by other groups (<a href="../supplement299/B16.asp#10">10</a>,<a href="../supplement299/B16.asp#11">11</a>), but it appeared that treatment with nicotinamide delayed rather
    than completely prevented disease development (<a href="../supplement299/B16.asp#10">10</a>). In their
    seminal study, Yamada et al. (<a href="../supplement299/B16.asp#9">9</a>) also observed reversal of overt
    diabetes when treatment with nicotinamide was begun at diagnosis of hyperglycemia. This
    latter finding could not be confirmed in our own studies (A. Faust, H.K., unpublished
    observations).</font></p>
    <p><font size="3">Several groups also tried nicotinamide in the BB rat model of human type
    1 diabetes (<a href="../supplement299/B16.asp#12">12</a>&#150;<a href="../supplement299/B16.asp#15">15</a>). The majority of
    these studies did not observe a significant effect of nicotinamide on disease development.
    However, all BB rat studies documented a trend toward diabetes suppression in the
    nicotinamide group compared with the control group. Therefore, it is probable that the
    descriptive statistics performed on the BB rat studies would come up with a 35&#150;45%
    suppression of diabetes incidence in this animal model due to nicotinamide treatment
    within the observation period reported.</font></p>
    <p><font size="3">Taken together, the observations in NOD mice and the BB rat indicate
    that nicotinamide has a differential protective effect against the development of diabetes
    in the two animal models. At present, there is no experimental evidence to explain this
    discrepancy. However, it may be speculated that the pathophysiological processes involved
    in immune-mediated islet cell destruction in the two rodent strains include phases that
    differ in their sensitivity to nicotinamide.</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td><img src="http://journal.diabetes.org/DCStables/images/047.T1.JPG" alt="047.T1.JPG (30006 bytes)" WIDTH="205" HEIGHT="200"></td>
      </tr>
    </table>
    </center></div><p><font size="3"><strong>NICOTINAMIDE IN TYPE 1 DIABETES&#151;</strong>
    The available evidence clearly indicates that treatment with high-dose nicotinamide exerts
    some protective effect on <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cell function in humans. In a recent study, we
    analyzed all published trials of nicotinamide in recent-onset type 1 diabetes, i.e.,
    treatment started within weeks of diagnosis (<a href="../supplement299/B16.asp#16">16</a>). Of these, 10
    randomized and controlled trials were eligible for meta-analysis. As shown in Table 1,
    combined analysis of a total of 158 nicotinamide-treated and 129 control patients revealed
    significantly better preservation of basal C-peptide secretion in the
    nicotinamide-receiving cohort after 1 year. Subanalysis of the five placebo-controlled
    trials gave the same result (<a href="../supplement299/B16.asp#16">16</a>). Despite this outcome, the
    effects were not substantial enough to improve clinical parameters of nicotinamide-treated
    individuals within the study period of 12 months.</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td><p align="center"><img src="http://journal.diabetes.org/converted_files/images/005994a.gif" alt="005994a.gif (11178 bytes)" WIDTH="520" HEIGHT="418"></td>
      </tr>
      <tr>
        <td><font size="3"><strong>Figure 1&#151;</strong><i>Chemical structure of nicotinamide.</i></font></td>
      </tr>
    </table>
    </center></div><p><font size="3"><strong>NICOTINAMIDE: PHARMACOLOGY&#151;</strong>
    Nicotinamide (niacinamide, vitamin B<sub>3</sub>) is a water-soluble amide of nicotinic
    acid (Fig. 1). Several different pharmacological actions have been reported for
    nicotinamide, and contrasting views have been expressed as to which of these properties
    contribute or account for the protective effect of nicotinamide on the <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cell.</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td><img src="http://journal.diabetes.org/converted_files/images/005995a.gif" alt="005994a.gif (11178 bytes)" WIDTH="600" HEIGHT="453"></td>
      </tr>
      <tr>
        <td><font size="3"><strong>Figure 2&#151;</strong><i>Concentration dependency of
        nicotinamide's pharmacological actions. The expected peak levels in vivo after high-dose
        nicotinamide administration are 0.3&#150;1 mmol/l.</i></font></td>
      </tr>
    </table>
    </center></div><p><font size="3">It is important to note that some of the actions of
    nicotinamide require high concentrations that may not be reached in vivo. As roughly
    sketched in Fig. 2, nicotinamide already acts as a precursor of NAD<sup>+</sup></font>at
    low concentrations. Nicotinamide is able to scavenge oxygen radicals, although it is not a
    potent antioxidant. However, it does not scavenge nitric oxide (NO), in contrast to some
    lipophilic antioxidants, such as vitamin E (<a href="../supplement299/B16.asp#17">17</a>,<a href="../supplement299/B16.asp#18">18</a>). This property probably becomes relevant at concentrations close
    to 1 mmol/l or above<font size="3">. Because its carbamoyl group is attached to an
    aromatic ring, nicotinamide is a specific inhibitor of ADP-ribosyl transferases. The 50%
    inhibition concentration of nicotinamide for poly(ADP-ribose)polymerase (PARP) is ~0.1
    mmol/l (<a href="../supplement299/B16.asp#19">19</a>,<a href="../supplement299/B16.asp#20">20</a>). The ability of
    nicotinamide to inhibit (mono)ADP-ribosyl transferases (ADPRT) is much lower and requires
    a concentration 110 times higher than IC<sub>50</sub> (<a href="../supplement299/B16.asp#19">19</a>).
    Concentrations of <u>&gt;</u>10 mmol/l are required for nicotinamide to interfere with the
    transcription of a small number of genes, including inducible nitric oxide synthase (<a href="../supplement299/B16.asp#21">21</a>). At concentrations of <u>&gt;</u>25 mmol/l, a more general
    inhibition of gene expression and protein synthesis was observed (<a href="../supplement299/B16.asp#22">22</a>).</font></p>
    <p><font size="3">Although this list of nicotinamide actions is far from complete, it has
    led to controversial views on how nicotinamide might work. A simple solution is to
    consider the concentration dependency of the various pharmacological actions and to relate
    this to plasma levels of nicotinamide obtained in humans. Studies of nicotinamide levels
    in the plasma of probands receiving high doses of nicotinamide, similar to those applied
    in type 1 diabetes prevention studies, reported peak levels around 0.3&#150;1.1 mmol/l (<a href="../supplement299/B16.asp#23">23</a>,<a href="../supplement299/B16.asp#24">24</a>). This renders the actions of
    nicotinamide that are seen only at or above millimolar concentrations less probable as
    being responsible for the antidiabetic effect of nicotinamide in vivo.</font></p>
    <p><font size="3"><strong>PARP AS TARGET OF NICOTINAMIDE IN MICE&#151;</strong> We tested
    the hypothesis that PARP is the key target of nicotinamide in vivo by analyzing mice with
    an inactivated PARP gene. PARP is a nuclear enzyme that is activated by DNA strand breaks
    and allows for a rapid response to DNA damage, such as that induced during the cells'
    normal life cycle or occurring after chemical, physical, or inflammatory insults (<a href="../supplement299/B16.asp#25">25</a>,<a href="../supplement299/B16.asp#26">26</a>). The sudden induction of widespread
    DNA damage leads to a rapid, excessive activation of the enzyme; in certain sensitive
    cells, this results in a critical reduction of the cytoplasmatic pool of NAD<sup>+</sup></font>
    that serves as a substrate for PARP to synthesize large polymers consisting of ADP
    subunits (<a href="../supplement299/B16.asp#25">25</a>).</p>
    <p><font size="3">We used the animal model of streptozotocin (STZ)-induced diabetes to
    determine whether PARP is the target of the antidiabetic action of nicotinamide. Treatment
    of mice with STZ causes selective <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cell death and diabetes (<a href="../supplement299/B16.asp#27">27</a>,<a href="../supplement299/B16.asp#28">28</a>). Cellular insults caused by STZ resemble those seen after
    exposure of <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cells to mediators of islet inflammation, such as activated
    macrophages or endothelial cells, cytokines, oxygen radicals, or NO (<a href="../supplement299/B16.asp#29">29</a>&#150;<a href="../supplement299/B16.asp#31">31</a>). <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cell death includes both necrosis and apoptosis
    pathways during which activation of PARP is observed. The administration of a single high
    dose of STZ is a means for targeting a toxic attack involving NO and other radicals (<a href="../supplement299/B16.asp#30">30</a>&#150;<a href="../supplement299/B16.asp#32">32</a>) to the pancreatic <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cells
    of experimental animals.</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td><p align="center"><img src="http://journal.diabetes.org/converted_files/images/005996a.gif" alt="005994a.gif (11178 bytes)" WIDTH="600" HEIGHT="463"></td>
      </tr>
      <tr>
        <td><font size="3"><strong>Figure 3&#151;</strong><i>Effects of STZ administration on
        blood glucose levels. At day 0, groups of five to eight animals received a single
        intraperitoneal injection of STZ (160 mg/kg body wt) or a corresponding volume of sodium
        citrate buffer alone as sham treatment (control). The intraperitoneal administration of
        nicotinamide (NA) (500 mg/kg body wt) was performed 6 h before the STZ injection or the
        sham treatment. The data show means � SD of blood glucose concentrations. *</i>P&lt;<i>
        0.01. Adapted from Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, Wagner EF,
        Kolb H, submitted for publication.</i></font></td>
      </tr>
    </table>
    </center></div><p><font size="3">Treatment of 129SV mice with a single high dose of STZ
    (160 mg/kg) caused the development of acute hyperglycemia within 3 days (Fig. 3). Diabetes
    development was almost completely suppressed when mice received 500 mg/kg of nicotinamide
    6 h prior to STZ (Fig. 3). When the same experiment was repeated with a 129SV mouse line
    that completely lacks PARP enzyme activity (<i>PARP<sup>&#150;/&#150;</sup></i>) as a
    consequence of PARP gene disruption (<a href="../supplement299/B16.asp#33">33</a>), STZ administration
    failed to induce hyperglycemia (Fig. 3). Even at a dose of 240 mg/kg body weight, STZ was
    unable to affect the normal blood glucose level of <i>PARP<sup>&#150;/&#150;</sup></i>
    mice (data not shown). Further follow-up of the animals up to 5 days confirmed stable high
    blood glucose level in <i>PARP<sup>+/+</sup></i> mice and continuous normoglycemia in <i>PARP<sup>&#150;/&#150;</sup></i>
    mice (data not shown). Histological analysis revealed a significant preservation of the
    percentage of the insulin-positive area within islets and of the amount of insulin
    extractable from total pancreas in STZ-treated <i>PARP<sup>&#150;/&#150;</sup></i> mice
    compared with <i>PARP<sup>+/+</sup></i> mice (V. Burkart, Z.-Q. Wang, J. Radons, B.
    Heller, Z. Herceg, L. Stingl, E.F. Wagner, H.K., unpublished observations).</font></p>
    <p><font size="3">Taken together, these data demonstrate a key role of PARP in <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cell
    death in vivo. Mice with a disrupted PARP gene appeared to be completely resistant against
    the diabetogenic actions of STZ. Hence, the antidiabetic actions of nicotinamide in the
    STZ model are explained by its property to inhibit PARP. Considering that nicotinamide
    also interferes with diabetes development in NOD mice, it seems probable that the same
    mechanism applies.</font></p>
    <p><font size="3"><strong>TARGETS OF NICOTINAMIDE ACTION IN HUMANS&#151;</strong>
    Nicotinamide has been used at doses 10&#150;200 times above the recommended vitamin
    allowance to treat a variety of different conditions, including skin diseases,
    neurological disorders, and type 1 diabetes. In the course of these studies, several
    pharmacological effects have been observed. These biochemical actions clearly differ from
    that of nicotinic acid, i.e., a negligible portion of nicotinamide is metabolized to
    nicotinic acid, mostly due to bacterial activity, such as in the oral flora (<a href="../supplement299/B16.asp#34">34</a>).</font></p>
    <p><font size="3">An important property of nicotinamide is the enhancement of radiation
    damage of tumors at similar plasma concentrations as in mice (<a href="../supplement299/B16.asp#35">35</a>).
    Initially, it was thought that the sensitization of tumor cells toward radio- or
    chemotherapy by nicotinamide was due to the inhibition of DNA repair, which enhanced DNA
    damage in treated tumor cells (<a href="../supplement299/B16.asp#36">36</a>&#150;<a href="../supplement299/B16.asp#38">38</a>).
    More recently, it became evident that the main mechanism involved is the reduction of
    hypoxia in tumors by increasing the proportion of tumor that is well oxygenated, i.e., by
    improving microvascular blood flow (<a href="../supplement299/B16.asp#39">39</a>&#150;<a href="../supplement299/B16.asp#43">43</a>).
    This finding may be related to the downregulation of adhesion molecules (ICAM-1 and
    HLA-DR) on activated human endothelial cells in the presence of nicotinamide (<a href="../supplement299/B16.asp#44">44</a>).</font></p>
    <p><font size="3">An anti-inflammatory action of nicotinamide has been reported that
    especially affects neutrophil chemotaxis (<a href="../supplement299/B16.asp#45">45</a>), as also seen in a
    mouse arthritis model (<a href="../supplement299/B16.asp#46">46</a>).</font></p>
    <p><font size="3">Another target of nicotinamide action in humans is insulin homeostasis.
    It has been reported that nicotinamide dosing increases insulin resistance in individuals
    with subclinical islet autoimmunity (<a href="../supplement299/B16.asp#47">47</a>), whereas no such effects
    were seen in normal probands (<a href="../supplement299/B16.asp#48">48</a>,<a href="../supplement299/B16.asp#49">49</a>).
    Our own experience with long-term nicotinamide administration to individuals at risk of
    type 1 diabetes suggests a depressive effect of nicotinamide on the first-phase insulin
    response to intravenous glucose (<a href="../supplement299/B16.asp#50">50</a>).</font></p>
    <p><font size="3">In conclusion, nicotinamide seems to target different cells in humans,
    such as tumor cells, the microvasculature, or <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cells.
    We regard it as probable that in the different tissues the mechanism of nicotinamide
    action is the same. Taking this thought further, the primary candidate molecule for
    interaction with nicotinamide is the family of ADP-ribosylating enzymes. Among these, PARP
    is inhibited most avidly by nicotinamide, followed by ADP-ribosyl transferases. Based on
    our studies of PARP knockout mice, described above, we therefore assume that much of the
    pharmacological effects of nicotinamide are due to the partial suppression of PARP
    activity, with a possible contribution of the lesser suppression of ADPRTs.</font></p>
    <p><font size="3">Indeed, the modulatory effect of nicotinamide on major
    histocompatibility complex (MHC) class II expression probably is due to the interaction
    with PARP. When PARP activity was modulated by transfection with PARP-expressing plasmids,
    again modulation of MHC class II expression was noted (<a href="../supplement299/B16.asp#51">51</a>,<a href="../supplement299/B16.asp#52">52</a>). This clearly demonstrates that PARP activity modulates gene
    expression, besides facilitating DNA repair.</font></p>
    <p><font size="3">Another important function of PARP is the regulation of apoptosis. An
    early step of the pathway leading to programmed cell death is the cleavage of PARP by the
    cysteine protease apopain (CPP32) (<a href="../supplement299/B16.asp#53">53</a>). Inhibition of PARP
    cleavage is associated with protection from apoptosis (<a href="../supplement299/B16.asp#53">53</a>,<a href="../supplement299/B16.asp#54">54</a>). Pharmacological inhibition of PARP may mimic functional
    consequences of PARP cleavage. Indeed, administration of the nicotinamide-related PARP
    inhibitor 3-aminobenzamide was reported to enhance thymocyte apoptosis in mice (<a href="../supplement299/B16.asp#55">55</a>). In conclusion, inhibition of PARP may not only affect gene
    expression but also modulate apoptosis induction.</font></p>
    <p><font size="3">An additional pharmacological action of nicotinamide via inhibition of
    ADPRTs cannot be excluded, although there is only low affinity interaction with this
    subfamily of ADP-ribose synthesizing enzymes (<a href="../supplement299/B16.asp#19">19</a>,<a href="../supplement299/B16.asp#29">29</a>). Of particular interest is the possible interaction of
    nicotinamide with glycosylphosphatidyl-inositol&#150;anchored ADP-ribosyl transferases.
    These enzymes occur on the outer membrane of lymphocytes. The best known is CD38 (<a href="../supplement299/B16.asp#56">56</a>,<a href="../supplement299/B16.asp#57">57</a>), which was recently found to exert
    ADP-ribosyl cyclase and cADP-ribosyl hydrolase activities (<a href="../supplement299/B16.asp#58">58</a>).
    Antibodies to CD38 potentiate many biological activities of lymphocytes, in particular
    promoting B-cell proliferation. The latter may result in a Th2 bias, an immunoregulatory
    state preventing destructive insulitis (<a href="../supplement299/B16.asp#59">59</a>). In this context, it
    is of interest that murine CD38 is closely related to the RT6 antigen of rat T-cells, for
    which a diabetes protective function has been demonstrated in BB rats (<a href="../supplement299/B16.asp#60">60</a>).</font></p>
    <div align="center"><center><table border="1" cellpadding="2">
      <tr>
        <td><p align="center"><img src="http://journal.diabetes.org/converted_files/images/005997a.gif" alt="005997a.gif (11178 bytes)" WIDTH="600" HEIGHT="364"></td>
      </tr>
      <tr>
        <td><strong>Figure 4 &#151;</strong><em>Possible mechanism of pharmacological actions of
        nicotinamide in humans. The inhibition of PARP, and to a lesser extent of ADPRT, is
        proposed to affect functions of <font size="3"><img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19"></font>-cells,
        immune cells, and other cell types, such as the endothelium.</em></td>
      </tr>
    </table>
    </center></div><p><font size="3">As summarized in Fig. 4, the inhibition of
    ADP-ribosyl-transferring enzymes by nicotinamide modulates cell function and affects cell
    survival at several levels. These effects are not specific for <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cells
    but may also occur in other cell types, such as leukocytes or endothelial cells.</font></p>
    <p><font size="3"><strong>OUTLOOK&#151;</strong> Taken together, modulation of
    ADP-ribosylation probably represents a promising approach of cellular protection and
    immunoregulation. Whether the weak and nonselective inhibitor nicotinamide is the
    appropriate compound to test for the therapeutic potential of this approach presently
    cannot be judged.</font></p>
    <p><font size="3">The German multicenter trial of nicotinamide in individuals at risk of
    type 1 diabetes (DENIS) was terminated in 1997 because no major reduction of diabetes risk
    was observed in the nicotinamide versus placebo group (<a href="../supplement299/B16.asp#2">2</a>,<a href="../supplement299/B16.asp#50">50</a>). However, this trial had focused on individuals with high
    diabetes risk and assumed rapid disease progression, i.e., islet cell antibody positive
    siblings (3&#150;12 years of age) of patients with type 1 diabetes. Further information
    will come from an ongoing international trial of nicotinamide (ENDIT). The latter trial
    also includes islet cell antibody positive relatives at lower risk and will be able to
    detect much smaller effects of treatment on diabetes risk reduction (<a href="../supplement299/B16.asp#3">3</a>).</font></p>
    <hr>
    <p><font size="3"><strong>Acknowledgments&#151;</strong> This work was supported by the
    Deutsche Forschungsgemeinschaft (H.K.), the Bundesminister f�r Gesundheit, and the
    Minister f�r Wissenschaft und Forschung des Landes Nordrhein-Westfalen.</font></p>
    <hr>
    <p><font size="3"><strong>References<br>
    </strong><a name="1">1</a>. Elliott RB, Pilcher CC, Ferguson DM, Stewart AW: A population
    based strategy to prevent insulin-dependent diabetes using nicotinamide. <i>J Pediatr
    Endocrinol Metabol</i> 9:501&#150;509, 1996</font></p>
    <p><font size="3"><a name="2">2</a>. Lampeter EF: Intervention with nicotinamide in
    pre-type 1 diabetes: the Deutsche Nicotinamid Interventionsstudie&#151;DENIS. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8314411&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabete
    Metab </i>19:105&#150;109, 1993</a></font></p>
    <p><font size="3"><a name="3">3</a>. Gale EAM, Bingley PJ: Can we prevent IDDM? <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8026292&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    Care </i>17:339&#150;344, 1994</a></font></p>
    <p><font size="3"><a name="4">4</a>. Elliott RB, Chase HP: Prevention or delay of type 1
    (insulin-dependent) diabetes mellitus in children using nicotinamide. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1830860&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetologia
    </i>34:362&#150;365, 1991</a></font></p>
    <p><font size="3"><a name="5">5</a>. Herskowitz RD, Jackson RA, Soeldner JS, Eisenbarth
    GS: Pilot trial to prevent type 1 diabetes: progression to overt IDDM despite oral
    nicotinamide. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2529865&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Autoimmun </i>2:733&#150;737, 1989</a></font></p>
    <p><font size="3"><a name="6">6</a>. Manna R, Migliore A, Martin LS, Ferrara E, Ponte E,
    Marietti G, Scuderi F, Cristiano G, Ghirlanda G, Gambassi G: Nicotinamide treatment in
    subjects at high risk of developing IDDM improves insulin secretion. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1286017&amp;form=6&amp;db=m&amp;Dopt=b"><i>Br
    J Clin Pract </i>46:177&#150;179, 1992</a></font></p>
    <p><font size="3"><a name="7">7</a>. Lazarow A: Protection against alloxan diabetes. <i>Anat
    Rec </i>97:353, 1947</font></p>
    <p><font size="3"><a name="8">8</a>. Lazarow A, Liambies L, Tausch AJ: Protection against
    diabetes with nicotinamide. <i>J Lab Clin Med </i>36:249&#150;258, 1950</font></p>
    <p><font size="3"><a name="9">9</a>. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima
    H, Tarui S: Preventive and therapeutic effects of large-dose nicotinamide injections on
    diabetes associated with insulitis. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6219022&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    </i>31:749&#150;753, 1982</a></font></p>
    <p><font size="3"><a name="10">10</a>.&nbsp;Elliott RB, Pilcher CC, Stewart A, Ferguson D,
    McGregor MA: The use of nicotinamide in the prevention of type 1 diabetes. <i>Ann NY Acad
    Sci U S A </i>696:333&#150;343, 1993</font></p>
    <p><font size="3"><a name="11">11</a>. Yamamoto K, Miyagawa J, Itoh N, Nakajima H, Waguri
    M, Shimada T, Yasuda K, Kono N, Namba M, Kuwajima M, Hanafusa T, Matsuzawa Y:
    Differentiation of <img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-cells from ductal cells and acceleration of this process by
    nicotinamide: ultrastructural study on the non-obese diabetic (NOD) mouse with overt
    diabetes. <i>Biomed Res Tokyo </i>18:171&#150;178, 1997</font></p>
    <p><font size="3"><a name="12">12</a>.&nbsp;Kolb H, Schmidt M, Kiesel U: Immunomodulatory
    drugs in type 1 diabetes. In <i>Immunotherapy of Type 1 Diabetes and Selected Autoimmune
    Disorders. </i>Eisenbarth GS, Ed. Boca Raton, FL, CRC Press, 1989, p. 111&#150;122</font><a name="11"></p>
    <p></a><font size="3"><a name="13">13</a>. Sarri Y, Mendola J, Ferrer J, Gomis R:
    Preventive effects of nicotinamide administration on spontaneous diabetes of BB rats. <i>Med
    Sci Res </i>17:987&#150;988, 1989</font></p>
    <p><font size="3"><a name="14">14</a>. Hermitte L, Vialettes B, Atlef N, Payan MJ, Doll N,
    Scheimann A, Vague P: High dose nicotinamide fails to prevent diabetes in BB rats. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2535259&amp;form=6&amp;db=m&amp;Dopt=b"><i>Autoimmunity
    </i>5:79&#150;86, 1989</a></font></p>
    <p><font size="3"><a name="15">15</a>.&nbsp;Pan JQ, Chan EK, Cheta D, Schranz V, Charles
    MA: The effect of nicotinamide and glimepiride on diabetes prevention in BB rats. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7564897&amp;form=6&amp;db=m&amp;Dopt=b"><i>Life
    Sci </i>57:1525&#150;1532, 1995</a></font></p>
    <p><font size="3"><a name="16">16</a>. Pozzilli P, Browne PD, Kolb H: Meta-analysis of
    nicotinamide treatment in patients with recent-onset IDDM: the nicotinamide trialists. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8941464&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    Care </i>19:1357&#150;1363, 1996</a></font></p>
    <p><font size="3"><a name="17">17</a>.&nbsp;Andersen HU, Jorgensen KH, Egeberg J,
    Mandrup-Poulsen T, Nerup J: Nicotinamide prevents interleukin-1 effects on accumulated
    insulin release and nitric oxide production in rat islets of Langerhans. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8194662&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    </i>43:770&#150;777, 1994</a></font></p>
    <p><font size="3"><a name="18">18</a>. Burkart V, Gross-Eick A, Bellmann K, Radons J, Kolb
    H: Suppression of nitric oxide toxicity in islet cells by alpha-tocopherol. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7758579&amp;form=6&amp;db=m&amp;Dopt=b"><i>FEBS
    Lett </i>364:259&#150;263, 1995</a></font></p>
    <p><font size="3"><a name="19">19</a>. Rankin PW, Jacobson EL, Benjamin RC, Moss J,
    Jacobson MK: Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2538435&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Biol Chem </i>264:4312&#150;4317, 1989</a></font></p>
    <p><font size="3"><a name="20">20</a>.&nbsp;Banasik M, Komura H, Shimoyama M, Ueda K:
    Specific inhibitors of poly(ADP-ribose)synthetase and mono(ADP-ribosyl)transferase.<a name="14"> </a><a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1530940&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Biol Chem </i>267:1569&#150; 1575, 1992</a></font></p>
    <p><font size="3"><a name="21">21</a>. Pellatdeceunynck C, Wietzerbin J, Drapier JC:
    Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7506533&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochem
    J </i>297:53&#150;58, 1994</a></font></p>
    <p><font size="3"><a name="22">22</a>. Hauschildt S, Scheipers P, Bessler WG: Inhibitors
    of poly(ADP-ribose)polymerase suppress lipopolysaccharide-induced nitrite formation in
    macrophages. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1716889&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochem
    Biophys Res Commun </i>179:865&#150;871, 1991</a></font></p>
    <p><font size="3"><a name="23">23</a>.&nbsp;Petley A, Macklin B, Renwick AG, Wilkin TJ:
    The pharmacokinetics of nicotinamide in humans and rodents. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7859933&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    </i>44:152&#150;155, 1995</a></font></p>
    <p><font size="3"><a name="24">24</a>. Stratford MRL, Rojas A, Hall DW, Dennis MF, Dische
    S, Joiner MC, Hodgkiss RJ: Pharmacokinetics of nicotinamide and its effect on blood
    pressure, pulse and body temperature in normal human volunteers. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1410588&amp;form=6&amp;db=m&amp;Dopt=b"><i>Radiother
    Oncol </i>25:37&#150;42, 1992</a></font></p>
    <p><font size="3"><a name="25">25</a>.&nbsp;Satoh MS, Lindahl T: Role of
    poly(ADP-ribose)formation in DNA repair. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1549180&amp;form=6&amp;db=m&amp;Dopt=b"><i>Nature
    </i>356:356&#150;358, 1992</a></font></p>
    <p><font size="3"><a name="26">26</a>. DeMurcia G, Schreiber V, Molinete M, Saulier B,
    Poch O, Masson M, Niedergang C, Menissier DeMurcia J: Structure and function of
    poly(ADP-ribose)polymerase. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7898458&amp;form=6&amp;db=m&amp;Dopt=b"><i>Mol
    Cell Biochem </i>138:15&#150;24, 1994</a></font></p>
    <p><font size="3"><a name="27">27</a>.&nbsp;Rakieten N, Rakieten ML, Nadkarni MV: Studies
    on the diabetogenic action of streptozotocin (NSC-37917). <i>Cancer Chemother Rep </i>29:91&#150;98,
    1963</font></p>
    <p><font size="3"><a name="28">28</a>. Like AA, Rossini AA: Streptozotocin-induced
    pancreatic insulitis: new model of diabetes mellitus. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=180605&amp;form=6&amp;db=m&amp;Dopt=b"><i>Science
    </i>193:415&#150;417, 1976</a></font></p>
    <p><font size="3"><a name="29">29</a>.&nbsp;Rasschaert J, Eizirik DL, Malaisse WJ: Long
    term in vitro effects of streptozotocin, interleukin-1, and high glucose concentration on
    the activity of mitochondrial dehydrogenases and the secretion of insulin in pancreatic
    islets. <i>Endocrinol </i>130:3522&#150;3528, 1992</font></p>
    <p><font size="3"><a name="30">30</a>. Kolb H, Kr�ncke K-D: Lessons from the low dose
    streptozocin model in mice. <i>Diabetes Rev </i>1:116&#150;126, 1993</font></p>
    <p><font size="3"><a name="31">31</a>. Kr�ncke K-D, Fehsel K, Sommer A, Rodriguez M-L,
    Kolb-Bachofen V: Nitric oxide generation during cellular metabolization of the
    diabetogenic N-methyl-N-nitroso-urea streptozotocin contributes to islet cell DNA damage. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542008&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biol
    Chem Hoppe-Seyler </i>376:179&#150;185, 1995</a></font></p>
    <p><font size="3"><a name="32">32</a>.&nbsp;Turk J, Corbett JA, Ramanadham S, Bohrer A,
    McDaniel L: Biochemical evidence for nitric oxide formation from streptozotocin in
    isolated pancreatic islets. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7904159&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochem
    Biophys Res Commun </i>197:1458&#150;1464, 1993</a></font></p>
    <p><font size="3"><a name="33">33</a>. Wang Z-Q, Auer B, Stingl L, Berghammer H, Haidacher
    D, Schwaiger M, Wagner EF: Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally
    but are susceptible to skin disease. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7698643&amp;form=6&amp;db=m&amp;Dopt=b"><i>Genes
    Dev </i>9:509&#150;520, 1995</a></font></p>
    <p><font size="3"><a name="34">34</a>.&nbsp;Stratford MR, Dennis MF, Hoskin P, Phillips H,
    Hodgkiss RJ, Rojas A: Nicotinamide pharmacokinetics in humans: effect of gastric acid
    inhibition, comparison of rectal vs oral administration and the use of saliva for drug
    monitoring. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8679452&amp;form=6&amp;db=m&amp;Dopt=b"><i>Br
    J Cancer </i>74:16&#150;21, 1996</a></font></p>
    <p><font size="3"><a name="35">35</a>. Horsman MR, Hoyer M, Honess DJ, Dennis IF,
    Overgaard J: Nicotinamide pharmacokinetics in humans and mice: a comparative assessment
    and the implications for radiotherapy. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8356223&amp;form=6&amp;db=m&amp;Dopt=b"><i>Radiother
    Oncol </i>27:131&#150;139, 1993</a></font></p>
    <p><font size="3"><a name="36">36</a>.&nbsp;Riklis E, Kol R, Marko R: Trends and
    developments in radioprotection: the effect of nicotinamide on DNA repair. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1969902&amp;form=6&amp;db=m&amp;Dopt=b"><i>Int
    J Radiat Biol </i>57:699&#150;708, 1990</a></font></p>
    <p><font size="3"><a name="37">37</a>.&nbsp;Chen G, Zeller WJ: Multiple effects of
    3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and
    DDP-resistant rat ovarian tumor cell lines. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423242&amp;form=6&amp;db=m&amp;Dopt=b"><i>Cancer
    Lett </i>67:27&#150;33, 1992</a></font></p>
    <p><font size="3"><a name="38">38</a>. Olsson AR, Sheng Y, Pero RW, Chaplin DJ, Horsman
    MR: DNA damage and repair in tumour and non-tumour tissues of mice induced by
    nicotinamide. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8695350&amp;form=6&amp;db=m&amp;Dopt=b"><i>Br
    J Cancer </i>74:368&#150;373, 1996</a></font></p>
    <p><font size="3"><a name="39">39</a>.&nbsp;Horsman MR: Nicotinamide and other benzamide
    analogs as agents for overcoming hypoxic cell radiation resistance in tumors: a review. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7546822&amp;form=6&amp;db=m&amp;Dopt=b"><i>Acta
    Oncologica </i>34:571&#150;587, 1995</a></font></p>
    <p><font size="3"><a name="40">40</a>.&nbsp;Thomas CD, Prade M, Guichard M: Tumour
    oxygenation, radiosensitivity, and necrosis before and/or after nicotinamide, carbogen and
    perflubron emulsion administration. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7775835&amp;form=6&amp;db=m&amp;Dopt=b"><i>Int
    J Rad Biol </i>67:597&#150;605, 1995</a></font></p>
    <p><font size="3"><a name="41">41</a>. Price MJ, Li LT, Tward JD, Bublik I, McBride WH,
    Lavey RS: Effect of nicotinamide and pentoxifylline on normal tissue and FSa tumor
    oxygenation. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7779428&amp;form=6&amp;db=m&amp;Dopt=b"><i>Acta
    Oncologica </i>34:391&#150;395, 1995</a></font></p>
    <p><font size="3"><a name="42">42</a>.&nbsp;Hirst DG, Kennovin GD, Tozer GM, Prise VE,
    Flitney EW: The modification of blood flow in tumours and their supplying arteries by
    nicotinamide. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7779429&amp;form=6&amp;db=m&amp;Dopt=b"><i>Acta
    Oncologica </i>34:397&#150;400, 1995</a></font></p>
    <p><font size="3"><a name="43">43</a>.&nbsp;Peters CE, Chaplin DJ, Hirst DG: Nicotinamide
    reduces tumour interstitial fluid pressure in a dose-dependent manner. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9135442&amp;form=6&amp;db=m&amp;Dopt=b"><i>Br
    J Radiol </i>70:160&#150;167, 1997</a></font></p>
    <p><font size="3"><a name="44">44</a>. Hiromatsu Y, Sato M, Yamada K, Nonaka K: Inhibitory
    effects of nicotinamide on recombinant human interferon-gamma-induced intercellular
    adhesion molecule-1 (ICAM-1) and HLA-DR antigen expression on cultured human endothelial
    cells. <i>Immunology Lett </i>31:35&#150;40, 1991</font></p>
    <p><font size="3"><a name="45">45</a>.&nbsp;Berk MA, Lorinez AL: The treatment of bullous
    pemphigoid with tetracycline and niacinamide.<a name="24"> </a><a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2940979&amp;form=6&amp;db=m&amp;Dopt=b"><i>Arch
    Dermatol </i>122:670&#150;674, 1986</a></font></p>
    <p><font size="3"><a name="46">46</a>. Miesel M, Kurpisz M, Kr�ger H: Modulation of
    inflammatory arthritis by inhibition of poly(ADP-ribose)polymerase. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7628865&amp;form=6&amp;db=m&amp;Dopt=b"><i>Inflammation
    </i>19:379&#150;387, 1995</a></font></p>
    <p><font size="3"><a name="47">47</a>.&nbsp;Greenbaum CJ, Kahn SE, Palmer JP:
    Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8866571&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    </i>45:1631&#150;1634, 1996</a></font></p>
    <p><font size="3"><a name="48">48</a>. Paul TL, Hramiak IM, Mahon JL, Freeman D, Atkinson
    P, Finegood DT, Dupre J: Nicotinamide and insulin sensitivity (Letter). <i>Diabetologia </i>36:369,
    1993</font></p>
    <p><font size="3"><a name="49">49</a>. Bingley PJ, Caldas G, Bonfanti R, Gale EA:
    Nicotinamide and insulin secretion in normal subjects. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8359586&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetologia
    </i>36:675&#150;677, 1993</a></font></p>
    <p><font size="3"><a name="50">50</a>.&nbsp;Lampeter EF, Klinghammer A, Scherbaum WA,
    Heinze E, Haastert B, Giani G, Kolb H, the DENIS Group: The Deutsche Nicotinamide
    Intervention Study: an attempt to prevent type 1 diabetes.<a name="26"> </a><a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9604880&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes</i>
    47:980&#150;984, 1998</a></font></p>
    <p><font size="3"><a name="51">51</a>. Nomura I, Kurashige T, Taniguchi T: Inhibitory
    effect of interferon-gamma-dependent induction of major histocompatibility complex class
    II antigen by expressing exogenous poly(ADP-ribose)synthetase gene. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902098&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochem
    Biophys Res Commun </i>175:685&#150;689, 1991</a></font></p>
    <p><font size="3"><a name="52">52</a>.&nbsp;Tomoda T, Kurashige K, Taniguchi T: Inhibition
    of interferon-gamma-induced and phorbol ester-induced HLA-DR and interleukin-1 production
    by the expression of a transfected poly(ADP-ribose)synthetase gene in human leukemia THP-1
    cells. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1317213&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochim
    Biophys Acta </i>1135:79&#150;83, 1992</a></font></p>
    <p><font size="3"><a name="53">53</a>. Nicholson DW, Ali A, Thornberry NA, Vaillancourt
    JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM,
    Smulson ME, Yamin T-T, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3
    protease necessary for mammalian apoptosis. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7596430&amp;form=6&amp;db=m&amp;Dopt=b"><i>Nature
    </i>376:37&#150;43, 1995</a></font></p>
    <p><font size="3"><a name="54">54</a>.&nbsp;Dimmeler S, Haendeler J, Nehls M, Zeiher AM:
    Suppression of apoptosis by nitric oxide via induction of interleukin-1<img src="../supplement299/converted%20files/symbollibrary/beta.gif" align="absbottom" WIDTH="15" HEIGHT="19">-converting
    enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9034139&amp;form=6&amp;db=m&amp;Dopt=b"><i>J
    Exp Med </i>185:601&#150;607, 1997</a></font></p>
    <p><font size="3"><a name="55">55</a>. Hoshino J, Koeppel C, Westhauer E: 3-aminobenzamide
    enhances dexamethasone-mediated mouse thymocyte depletion in vivo: implication for a role
    of poly ADP-ribosylation in the negative selection of immature thymocytes. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7803485&amp;form=6&amp;db=m&amp;Dopt=b"><i>Biochim
    Biophys Acta </i>1201:516&#150;522, 1994</a></font></p>
    <p><font size="3"><a name="56">56</a>. Lund F, Solvason N, Grimaldi JC, Parkhouse RME,
    Howard M: Murine CD38: an immunoregulatory ectoenzyme. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7576049&amp;form=6&amp;db=m&amp;Dopt=b"><i>Immunol
    Today </i>16:469&#150;473, 1995</a></font></p>
    <p><font size="3"><a name="57">57</a>.&nbsp;Wang J, Nemoto E, Dennert G: Regulation of
    cytotoxic T cell functions by GPI-anchored ecto-ADP-ribosyltransferase. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9193654&amp;form=6&amp;db=m&amp;Dopt=b"><i>Adv
    Exp Med Biol </i>419:191&#150;201, 1997</a></font></p>
    <p><font size="3"><a name="58">58</a>. Yasue T, Nishizumi N, Aizawa S, Yamamoto T, Miyake
    K, Mizoguchi C, Uehara S, Kikuchi Y, Takatsu K: A critical role of lyn and fyn for B cell
    responses to CD38 ligation to interleukin 5. <i>Proc Natl Acad Sci U S A </i>94:10307&#150;10312,
    1997</font></p>
    <p><font size="3"><a name="59">59</a>.&nbsp;Kolb H: Benign versus destructive insulitis. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9307887&amp;form=6&amp;db=m&amp;Dopt=b"><i>Diabetes
    Metab Rev </i>13:139&#150;146, 1997</a></font></p>
    <p><font size="3"><a name="60">60</a>. Waite DJ, Appel MC, Handler ES, Mordes JP, Rossini
    AA, Greiner DL: Ontogeny and immunohistochemical localization of thymus-dependent and
    thymus-independent RT6+ cells in the rat. <a href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8669488&amp;form=6&amp;db=m&amp;Dopt=b"><i>Am
    J Pathol </i>148:2043&#150;2056, 1996</a></font></p>
    <hr>
    <p><font size="3">From the Diabetes Research Institute at the University of D�sseldorf,
    D�sseldorf, Germany.</font></p>
    <p><font size="3">Address correspondence and reprint requests to Hubert Kolb, Diabetes
    Research Institute, Auf'm Hennekamp 65, D-40225 D�sseldorf, Germany. E-mail: <a href="mailto:kolb@dfi.uni-duesseldorf.de">kolb@dfi.uni-duesseldorf.de</a>.</font></p>
    <p><font size="3">Received for publication 27 May 1998 and accepted in revised form 6
    November 1998.</font></p>
    <p><font size="3"><strong>Abbreviations:</strong> ADPRT, (mono)ADP-ribosyl transferase;
    MHC, major histocompatibility complex; PARP, poly(ADP-ribose)polymerase; STZ,
    streptozotocin.</font></p>
    <p><font size="3">This article is based on a presentation at a satellite symposium of the
    16th International Diabetes Federation Congress. The symposium and the publication of this
    article were made possible by educational grants from Hoechst Marion Roussel AG.</font></p>
    <hr>
    <p align="center"><a href="../../../../CareSup2March99.asp"><font size="3"><strong>Return
    to Supplement Contents</strong></font></a></p>
    <p align="center"><font size="1"><b>Copyright � 1999 American Diabetes Association</b> <br>
    <b>Last updated: 3/99<br>
    For ADA Related Issues contact</b> <a href="mailto:%22CustomerService@diabetes.org%22">CustomerService@diabetes.org</a></font></p>
    <p align="center"><font size="1"><b>For Technical Issues contact</b> <a href="mailto:%22webmaster@diabetes.org%22">webmaster@diabetes.org</a></font></td>
  </tr>
</table>
</div>
</body>
</html>
